EDT Stock Overview Focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Spectral Medical Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Spectral Medical Historical stock prices Current Share Price CA$0.48 52 Week High CA$0.75 52 Week Low CA$0.36 Beta 0.92 1 Month Change -14.91% 3 Month Change -25.38% 1 Year Change 27.63% 3 Year Change 94.00% 5 Year Change -32.64% Change since IPO -98.67%
Recent News & Updates
New minor risk - Market cap size Dec 12
Spectral Medical Provides November Tigris Trial Update Dec 03
Third quarter 2024 earnings released: CA$0.035 loss per share (vs CA$0.012 loss in 3Q 2023) Nov 09
Spectral Medical Inc. Provides October Tigris Trial Update Nov 05
Spectral Medical Inc. Provides September Tigris Trial Update Oct 04
Independent Chairman of the Board recently sold CA$98k worth of stock Sep 18 See more updates
New minor risk - Market cap size Dec 12
Spectral Medical Provides November Tigris Trial Update Dec 03
Third quarter 2024 earnings released: CA$0.035 loss per share (vs CA$0.012 loss in 3Q 2023) Nov 09
Spectral Medical Inc. Provides October Tigris Trial Update Nov 05
Spectral Medical Inc. Provides September Tigris Trial Update Oct 04
Independent Chairman of the Board recently sold CA$98k worth of stock Sep 18
Spectral Medical Inc. Provides August Tigris Trial Update Sep 04
Second quarter 2024 earnings released: CA$0.016 loss per share (vs CA$0.014 loss in 2Q 2023) Aug 11
Spectral Medical Inc Provides July Tigris Trial Update Aug 02 Spectral Medical Inc. announced that it has received $1 million in funding Jul 24
Spectral Medical Inc. announced that it expects to receive $1 million in funding Jul 23
Spectral Medical Inc. Provides June Tigris Trial Update Jul 03
Independent Chairman of the Board exercised options to buy CA$102k worth of stock. Jun 09 Spectral Medical Inc. announced that it has received CAD 8.499564 million in funding May 31
First quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.006 loss in 1Q 2023) May 13 Spectral Medical Inc. announced that it expects to receive CAD 8.499564 million in funding May 10
Spectral Medical Inc. Provides Tigris Trial Update May 08
Spectral Medical Provides Tigris Trial Update Apr 11
Less than half of directors are independent Apr 05
Price target increased by 13% to CA$1.80 Apr 03
Spectral Medical Inc. Announces Board Changes Apr 02
Full year 2023 earnings: EPS and revenues miss analyst expectations Apr 01
Spectral Medical Inc., Annual General Meeting, Jun 07, 2024 Mar 29
New minor risk - Market cap size Mar 13
Spectral Medical Inc. Provides Update on the Company's Tigris Trial Mar 01
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients Feb 16
Spectral Medical Inc. Provides Early February Tigris Trial Update Feb 07
Spectral Medical Provides January Tigris Trial Update Jan 30
Spectral Medical Inc. l Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial Jan 10
Spectral Medical Inc. Provides November Tigris Trial Update Dec 05
Spectral Medical Inc. Announces Executive Changes Dec 02
Spectral Medical Inc. Announces Executive Changes Dec 01
Spectral Medical Inc. Announces Publication of Tigris Trial Methods Paper Nov 17
Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat Nov 11
Spectral Medical Provides Tigris Trial Update Nov 09
New minor risk - Shareholder dilution Sep 15 Spectral Medical Inc. announced that it has received CAD 6.217075 million in funding Sep 08
Spectral Medical Inc. announced that it expects to receive CAD 5 million in funding from Paradigm Capital Inc. Aug 11
Second quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.011 loss in 2Q 2022) Aug 10
Spectral Medical Inc. Announces Tigris Clinical Trial Update Jul 26
Spectral Medical Inc. Appoints David W. Feigal to Its Board of Directors Jun 28
Spectral Medical Inc. Provides Update on Continued Favorable Tigris Clinical Trial Enrollment Jun 21
Spectral Medical Inc. Provides Update on Favorable Tigris Clinical Trial Enrollment May 31
Consensus revenue estimates increase by 186% May 26
Consensus revenue estimates decrease by 61%, EPS upgraded May 19
First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat May 13
Spectral Medical Inc. Announces Resignation of Jim Funk as Director May 06
No longer forecast to breakeven Mar 28
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 24
Spectral Medical Inc. Provides Update on Tigris Clinical Trial Jan 13
Consensus forecasts updated Dec 15
Consensus forecasts updated Nov 17
Price target decreased to CA$2.10 Nov 16
Forecast to breakeven in 2024 Nov 11 Spectral Medical Inc. announced that it has received CAD 6.8364 million in funding Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding Oct 07
Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding
Consensus forecasts updated Aug 19
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 12
Spectral Medical Provides Update on Tigris Clinical Trial Jul 21
US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ for the Treatment of Endotoxemic Septic Shock Jul 12
Spectral Medical Inc. Elects James Funk as Director Jun 22
Spectral Medical Inc. Appoints Sam Amory as Dialco, President May 17
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint May 13
Price target decreased to CA$2.10 Apr 27
Forecast breakeven date pushed back to 2024 Apr 27
Consensus revenue estimates fall by 44% Apr 08
Spectral Medical Inc., Annual General Meeting, Jun 09, 2022 Apr 02
Spectral Medical Inc. Through Its Wholly-Owned Subsidiary Dialco Medical Inc. Provides Clinical Trial Update on Tigris, A Follow on Study Designed to Build on Knowledge Gained from the Earlier Euphrates Trial Feb 12
We're Keeping An Eye On Spectral Medical's (TSE:EDT) Cash Burn Rate Feb 12
Forecast to breakeven in 2023 Nov 17 Shareholder Returns EDT CA Biotechs CA Market 7D -3.0% -2.5% -1.9% 1Y 27.6% 20.4% 17.8%
See full shareholder returns
Return vs Market: EDT exceeded the Canadian Market which returned 19.1% over the past year.
Price Volatility Is EDT's price volatile compared to industry and market? EDT volatility EDT Average Weekly Movement 8.5% Biotechs Industry Average Movement 12.3% Market Average Movement 8.1% 10% most volatile stocks in CA Market 17.5% 10% least volatile stocks in CA Market 2.9%
Stable Share Price: EDT has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: EDT's weekly volatility (8%) has been stable over the past year.
About the Company Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.
Show more Spectral Medical Inc. Fundamentals Summary How do Spectral Medical's earnings and revenue compare to its market cap? EDT fundamental statistics Market cap CA$132.94m Earnings (TTM ) -CA$25.00m Revenue (TTM ) CA$2.01m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EDT income statement (TTM ) Revenue CA$2.01m Cost of Revenue CA$1.21m Gross Profit CA$798.00k Other Expenses CA$25.80m Earnings -CA$25.00m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.088 Gross Margin 39.78% Net Profit Margin -1,246.31% Debt/Equity Ratio -41.2%
How did EDT perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/17 05:31 End of Day Share Price 2024/12/17 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Spectral Medical Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Dean Cormark Securities Inc. Scott McAuley Paradigm Capital, Inc. Andre Uddin Research Capital Corporation
Show 3 more analysts 
